Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Ionis Pharmaceuticals Community
NasdaqGS:IONS Community
3
Narratives
written by author
0
Comments
on narratives written by author
15
Fair Values set
on narratives written by author
Community Investing Ideas
Ionis Pharmaceuticals
Popular
Undervalued
Overvalued
Ionis Pharmaceuticals
AN
AnalystHighTarget
Consensus Narrative from 26 Analysts
Aging Demographic Trends And Precision Medicine Will Power Blockbuster Launches
Key Takeaways Accelerated adoption of new therapies, superior platform technology, and strong pipeline position Ionis for outsized revenue and margin growth beyond market expectations. Demographic trends, expanding indications, and global infrastructure create sustained growth opportunities across established and emerging markets.
View narrative
US$82.65
FV
47.9% undervalued
intrinsic discount
24.29%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
5 days ago
author updated this narrative
Ionis Pharmaceuticals
AN
AnalystLowTarget
Consensus Narrative from 26 Analysts
Escalating Payer Pressures Will Crush Margins Despite Fleeting Pipeline Optimism
Key Takeaways Revenue growth and profit margins are threatened by pricing pressures, regulatory scrutiny, and reliance on narrow indications and select partnerships. High competition, rising costs, and uncertain market adoption may lead to persistent operating losses and volatile financial performance.
View narrative
US$38.00
FV
13.4% overvalued
intrinsic discount
1.06%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
8 days ago
author updated this narrative
Ionis Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 26 Analysts
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Key Takeaways Expanding into larger patient populations and strong physician acceptance position Ionis for substantial market share gains and sustained top-line growth. Strategic partnerships, growing royalties, and a competitive edge in rare disease commercialization enhance financial resilience and support margin expansion.
View narrative
US$58.19
FV
25.9% undervalued
intrinsic discount
15.02%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
6 days ago
author updated this narrative
Your Valuation for
IONS
IONS
Ionis Pharmaceuticals
Your Fair Value
US$
Current Price
US$43.10
1.8% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-550m
2b
2015
2018
2021
2024
2025
2027
2030
Revenue US$2.3b
Earnings US$476.2m
Advanced
Set Fair Value